Synthetic biology company Intrexon files for a $125 million IPO

By Renaissance Capital,

Shutterstock photo

Intrexon, which is developing synthetic biology technologies, filed on Tuesday with the SEC to raise up to $125 million in an initial public offering. The Germantown, MD-based company, which was founded in 1998 and booked $16 million in collaboration revenue for the 12 months ended March 31, 2013, plans to list on the NYSE under the symbol XON. Intrexon initially filed confidentially on May 10, 2013. J.P. Morgan and Barclays are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks:

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by